Synageva BioPharma Announces Six-Month Data From Extension Study of SBC-102 (sebelipase alfa) in Late Onset LAL Deficiency at the American Association for Study of Liver Diseases Annual Meeting

Published: Nov 12, 2012

LEXINGTON, Mass.--(BUSINESS WIRE)--Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a clinical stage biopharmaceutical company developing therapeutic products for rare diseases, today announced six month results from an ongoing extension study of sebelipase alfa in adults with late onset Lysosomal Acid Lipase (LAL) Deficiency at the American Association for the Study of Liver Diseases (AASLD) annual meeting being held in Boston, MA, November 9-13, 2012.

Back to news